Key Points

  • Stock surge fueled by M&A speculation: WBD jumped 16.70% in one day and 146.34% over the past year, driven by rumors of acquisition talks with Paramount-Skydance and Netflix.
  • Earnings beat expectations: Q2 2025 EPS came in at $0.31 versus a forecasted $0.12 loss, with revenue reaching $9.81 billion.
  • Governance concerns linger: Despite strong results, shareholders rejected CEO David Zaslav’s $63.5 million pay package, highlighting tensions between management and investors.
hero

Meteoric Stock Performance Amid M&A Speculation

As of September 12, 2025, WBD shares closed at $18.87, soaring 16.70% in one trading day and recording a 146.34% annual gain. The rally has been largely fueled by media reports of a potential acquisition bid from Paramount-Skydance (PSKY), alongside speculation of a possible deal with Netflix. The surge pushed WBD to a 52-week high and outperformed the S&P 500 by a wide margin year-to-date. However, long-term returns remain below the index, highlighting that the recent momentum follows years of underperformance.

Strong Earnings but Ongoing Governance Issues

Beyond market rumors, Warner Bros. Discovery surprised investors with stronger-than-expected earnings. The company reported Q2 EPS of $0.31, compared to analysts’ projections of a $0.12 loss, and quarterly revenue of $9.81 billion. These fundamentals suggest a more solid basis for optimism, though the current price-to-earnings ratio of 60.87 reflects a steep valuation. At the same time, corporate governance issues came to the fore when shareholders voted overwhelmingly against CEO David Zaslav’s $63.5 million 2024 pay package. Although the company pledged to cut his compensation “significantly,” investors remain skeptical about the sincerity of the adjustment.

Looking Ahead: Can Momentum Outlast Speculation?

Warner Bros. Discovery stands at a pivotal moment. On one hand, strong financials and takeover speculation have propelled the stock to new highs. On the other, weak long-term returns, governance controversies, and a valuation well above analyst targets signal caution. The sustainability of this rally will depend on whether potential M&A moves materialize and whether management can rebuild investor trust.


Comparison, examination, and analysis between investment houses

Leave your details, and an expert from our team will get back to you as soon as possible

    * This article, in whole or in part, does not contain any promise of investment returns, nor does it constitute professional advice to make investments in any particular field.

    To read more about the full disclaimer, click here
    SKN | HSBC Raises S&P 500 Year-End Target to 8,100 as Earnings and AI Spending Support the Rally
    • orshu
    • 6 Min Read
    • ago 2 hours

    SKN | HSBC Raises S&P 500 Year-End Target to 8,100 as Earnings and AI Spending Support the Rally SKN | HSBC Raises S&P 500 Year-End Target to 8,100 as Earnings and AI Spending Support the Rally

      HSBC has raised its year-end target for the S&P 500 to 8,100 from 7,650, arguing that stronger corporate earnings

    • ago 2 hours
    • 6 Min Read

      HSBC has raised its year-end target for the S&P 500 to 8,100 from 7,650, arguing that stronger corporate earnings

    SKN | U.S. Sanctions on Iranian Airlines Intensify Economic Pressure as Middle East War Drives Oil Higher
    • Ronny Mor
    • 6 Min Read
    • ago 3 hours

    SKN | U.S. Sanctions on Iranian Airlines Intensify Economic Pressure as Middle East War Drives Oil Higher SKN | U.S. Sanctions on Iranian Airlines Intensify Economic Pressure as Middle East War Drives Oil Higher

    The United States expanded its economic campaign against Iran this week, imposing sweeping sanctions on the country's aviation sector as

    • ago 3 hours
    • 6 Min Read

    The United States expanded its economic campaign against Iran this week, imposing sweeping sanctions on the country's aviation sector as

    SKN | AstraZeneca’s Tozorakimab Clears Two Late-Stage COPD Trials, Strengthening Blockbuster Potential
    • omer bar
    • 6 Min Read
    • ago 4 hours

    SKN | AstraZeneca’s Tozorakimab Clears Two Late-Stage COPD Trials, Strengthening Blockbuster Potential SKN | AstraZeneca’s Tozorakimab Clears Two Late-Stage COPD Trials, Strengthening Blockbuster Potential

      AstraZeneca has strengthened the outlook for its respiratory pipeline after releasing full results from two successful late-stage trials of

    • ago 4 hours
    • 6 Min Read

      AstraZeneca has strengthened the outlook for its respiratory pipeline after releasing full results from two successful late-stage trials of

    SKN | European Markets Close Mixed as Euronext and Eurozone Stocks Advance While Broader Equities Lag
    • orshu
    • 6 Min Read
    • ago 4 hours

    SKN | European Markets Close Mixed as Euronext and Eurozone Stocks Advance While Broader Equities Lag SKN | European Markets Close Mixed as Euronext and Eurozone Stocks Advance While Broader Equities Lag

      European markets closed September 8 with a mixed performance, as modest gains in several major continental benchmarks contrasted with

    • ago 4 hours
    • 6 Min Read

      European markets closed September 8 with a mixed performance, as modest gains in several major continental benchmarks contrasted with